Blog
Insights on clinical trial matching, evidence-informed ranking, and AI in healthcare
June 9, 2026 • Post-conference synthesis
ASCO 2026 (June 5–9, Chicago) closed today. Seven patient-relevant takeaways: (1) pan-RAS goes prime time with daraxonrasib in two Phase 3s at once (RASolve 301 NSCLC + RASolute 304 adjuvant PDAC); (2) ivonescimab keeps stacking 1L Phase 3 readouts (HARMONi-7) and moves into TNBC, biliary, and colorectal; (3) T-DXd + pertuzumab is the new HER2+ MBC frontline standard after DESTINY-Breast09 and the Dec 2025 FDA approval; (4) HER3-DXd (patritumab deruxtecan) reaches registrational Phase 3 in breast (HERTHENA-Breast03); (5) tarlatamab matures from salvage into maintenance, SubQ, and EP-NEC + brain expansion; (6) cadonilimab (PD-1/CTLA-4) and rilvegostomig (PD-1/TIGIT) bispecifics continue global Phase 3 expansion; (7) the personalized mRNA cancer vaccine V940 (intismeran) reaches Phase 3 in adjuvant resected NSCLC (INTerpath-002). 32 NCT citations.
Read more →
June 3, 2026 • Pre-conference preview
ASCO 2026 (June 5–9, Chicago) is the conference where the NSCLC first-line landscape gets seriously crowded beyond pembrolizumab. TROP2 antibody-drug conjugates in 1L (TROPION-Lung08 Dato-DXd + pembro; TroFuse-007 sacituzumab tirumotecan + pembro). EGFR-mutant 1L combinations (TROPION-Lung14 Dato-DXd + osimertinib; FIRMOST firmonertinib adjuvant; DESTINY-Lung06 T-DXd HER2-mutant; SOHO-02 sevabertinib HER2-mutant TKI). KRAS pan-mutant (Krascendo 2 divarasib + pembro; KANDLELIT-013 calderasib adjuvant; RASolve 301 daraxonrasib RMC-6236). PD-1/VEGF bispecifics (HARMONi-7 ivonescimab 1L; ARTEMIDELung04 rilvegostomig vs pembro). mRNA vaccines (INTerpath-002 V940 intismeran adjuvant). ALK 1L (ALKAZAR neladalkib NVL-655). What NSCLC patients should ask their oncologist.
Read more →
June 1, 2026
May 2026 updates: 10 trial landscape pages for browse-before-you-search, 8 new drug pages (T-DXd, ivonescimab, cadonilimab, rilvegostomig, patritumab deruxtecan, daraxonrasib, ADI-PEG 20, tarlatamab), one-click prefill from cancer page to wizard, a faster treatment-history step that leads with line-of-therapy, and four ASCO 2026 patient previews.
Read more →
May 27, 2026 • Pre-conference preview
ASCO 2026 (May 29–June 2, Chicago) is the year prostate cancer gets multiple new mechanism classes in Phase 3 simultaneously. PSMA-targeted radioligand therapy expanding beyond Pluvicto: Novartis's actinium-225 alpha-emitter AAA817 (AcTFirst post-ARPI mCRPC; PSMAcTION post-Pluvicto-progression), Telix's antibody-based 177Lu-TLX591 (ProstACT Global), PEACE6-Poor Responders 177Lu-PSMA-617 in de novo mHSPC. New AR-pathway mechanisms (BMS-986365 in rechARge post-ARPI mCRPC; opevesostat CYP11A1 inhibitor in OMAHA-003). Saruparib PARP moving to mCSPC + BRCA-mutated localised high-risk. KLK2-comPAS pasritamig T-cell engager. What patients with prostate cancer should ask their oncologist.
Read more →
May 26, 2026 • Pre-conference preview
ASCO 2026 (May 29–June 2, Chicago) is the conference where KRAS finally becomes drug-able in pancreatic cancer. The Revolution Medicines RAS(ON) franchise — daraxonrasib in two registrational Phase 3 trials simultaneously (RASolute 303 first-line metastatic + RASolute 304 adjuvant resected), plus G12C/G12D/G12V variant-selective companion drugs (elironrasib, RMC-9805, RMC-5127, VS-7375) — is the headline. Plus IBI343 claudin 18.2 ADC Phase 3, ponsegromab cachexia, NABPLAGEM in BRCA-mutated, ivonescimab + chemo. What patients with PDAC should ask their oncologist.
Read more →
May 24, 2026 • Pre-conference preview
ASCO 2026 (May 29–June 2, Chicago) is where the CD3 T-cell engager class continues to mature. MajesTEC-9 (teclistamab monotherapy vs PVd/Kd in R/R myeloma) is the confirmed anchor abstract. Plus tarlatamab long-term follow-up and SubQ/outpatient data in ES-SCLC, CD20 lymphoma 1L combinations, and the solid-tumor TCE wave (CLDN18.2, MUC16, GPC3, KLK2, STEAP1, DLL3 beyond SCLC).
Read more →
May 23, 2026 • Pre-conference preview
Six weeks after AACR, ASCO 2026 (May 29–June 2, Chicago) is where Phase 3 readouts and registrational data land. DESTINY-Breast09 (T-DXd + pertuzumab, FDA-approved Dec 2025 for 1L HER2+ MBC) and TROPION-Breast02 (Datroway, FDA-approved May 22 for 1L TNBC) lead the program. Plus EGFR-ADCs in NPC, B7-H3 in lung, TROP2 expansion, and the first ADC + checkpoint-immunotherapy combinations entering 1L.
Read more →
May 5, 2026
Five April improvements: per-trial detail pages with eligibility breakdowns, confidence tiers and surfacing reasons that explain why each match, faster searches (NPC dropped from 23 minutes to 13 minutes), wider coverage by expanding cancer-name synonyms, and a smoother wizard.
Read more →
April 27, 2026
Tebentafusp 5-year survival data, conditional TCEs that activate only inside tumors, KRAS resistance paradox, and new trials for kidney cancer, sarcoma, and prostate cancer. How next-generation bispecific molecules are making immunotherapy work in solid tumors.
Read more →
April 26, 2026
CAR-T cells that don't burn out (KIR-CAR), mRNA injections that program your body to make cancer-fighting antibodies (100% response rate), personalized vaccines with 6-year protection, and the first patient treated with in vivo CAR engineering. The next wave of immune-based cancer treatments.
Read more →
April 24, 2026
92 antibody-drug conjugate projects were presented at AACR 2026. The field is moving toward bispecific ADCs targeting two proteins, dual-payload designs carrying two drugs, and novel payloads that overcome resistance. Here's what matters for patients looking for clinical trials.
Read more →
March 30, 2026
Four improvements this month: search results now arrive in 5–15 minutes, non-treatment studies are filtered out more accurately, cross-cancer drug signals inform ranking, and remission status is recognized to prevent irrelevant matches.
Read more →
March 15, 2026
No more blank text boxes. ClinTrialFinder now walks you through clinical trial matching step by step—asking the right questions for your specific disease, showing relevant treatment options and biomarkers, and adapting the number of steps based on your condition. No medical knowledge required.
Read more →
March 6, 2026
You open a trial matching tool and see a text box: "Describe your condition." What do you write? This guide breaks down exactly what information helps—cancer type, stage, prior treatments, biomarkers—and what you can skip.
Read more →
March 3, 2026
Most clinical trial matching tools stop at relevance and eligibility screening. We tested a real cancer patient case and found that TrialGPT-only ranking would have shown the wrong trials first—including a diagnostic imaging study ranked #1. Evidence-informed ranking correctly identified novel therapies as the best options.
Read more →
